[Form 4] Camp4 Therapeutics Corp Insider Trading Activity

Rhea-AI Filing Summary

Camp4 Therapeutics insider acquisition: Multiple 5AM-affiliated entities and Kush Parmar reported purchases and beneficial holdings of Camp4 Therapeutics (CAMP) common stock. On 09/11/2025 a purchase transaction (code P) was reported for 2,941,176 shares at $1.53 per share. The filing lists beneficial holdings following the transaction: 2,941,176 shares held by 5AM Ventures VII, L.P., 2,625,145 shares by 5AM Ventures VI, L.P., and 302,770 shares by 5AM Opportunities II, L.P. The reporting parties disclose indirect ownership through related general partner entities and state shared voting and investment power; the statements include disclaimers limiting beneficial ownership to pecuniary interest.

Positive

• Large non-derivative acquisition disclosed: 2,941,176 shares purchased at $1.53 per share on 09/11/2025
• Clear ownership mapping: Filing details indirect holdings across 5AM Ventures VII, 5AM Ventures VI, and 5AM Opportunities II with explicit disclaimers
• Proper signatures: Managing member Kush Parmar and related entities signed the Form 4, indicating procedural compliance

Negative

• None.

Insights

Securities Analyst

TL;DR: Significant insider purchase by 5AM-affiliated funds, showing increased stake but no new derivatives disclosed.

The Form 4 reports a single non-derivative acquisition on 09/11/2025: 2,941,176 shares purchased at $1.53 each by entities affiliated with 5AM Ventures VII. The filing clarifies ownership is held indirectly across multiple 5AM vehicles and includes standard disclaimers. For investors, this is a material ownership increase by affiliated venture funds but the filing contains no earnings, financing, or derivative activities to contextualize the purchase.

Corporate Governance Expert

TL;DR: Related-party disclosures are complete; managing members assert shared voting power with standard disclaimers.

The disclosure identifies 5AM Partners entities and named individuals (Dr. Kush Parmar and Andrew J. Schwab) as managing members with shared voting and investment power. Signatures from the managing member accompany the filing. The explanatory footnotes properly describe the chain of ownership and disclaimers, consistent with Section 16 reporting practices; no departures from standard governance disclosure conventions are evident in the text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

5AM Partners VI, LLC

(Last) (First) (Middle)

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		P		2,941,176	A	$1.53	2,941,176	I	By 5AM Ventures VII, L.P.(1)
Common Stock								2,625,145	I	By 5AM Ventures VI, L.P.(2)
Common Stock								302,770	I	By 5AM Opportunities II, L.P.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

5AM Partners VI, LLC

(Last) (First) (Middle)

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Ventures VI, L.P.

(Last) (First) (Middle)

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Opportunities II (GP), LLC

(Last) (First) (Middle)

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Opportunities II, L.P.

(Last) (First) (Middle)

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Partners VII, LLC

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Ventures VII, L.P.

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

PARMAR KUSH

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

2. The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

3. The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

	5AM Partners VI, LLC, By /s/ Kush Parmar, Managing Member	09/15/2025
	5AM Ventures VI, L.P., By: 5AM Partners VI, LLC, its General Partner, By /s/ Kush Parmar, Managing Member	09/15/2025
	5AM Opportunities II (GP), LLC, By /s/ Kush Parmar, Managing Member	09/15/2025
	5AM Opportunities II, L.P., By: 5AM Opportunities II (GP), LLC, its General Partner, By /s/ Kush Parmar, Managing Member	09/15/2025
	5AM Partners VII, LLC, By /s/ Kush Parmar, Managing Member	09/15/2025
	5AM Ventures VII, L.P. By: 5AM Partners VII, LLC, its General Partner, By /s/ Kush Parmar, Managing Member	09/15/2025
	/s/ Kush Parmar	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the Form 4 report for CAMP?

The Form 4 reports a non-derivative purchase of 2,941,176 shares of Camp4 Therapeutics on 09/11/2025 at $1.53 per share.

Which entities hold the shares disclosed in the filing for CAMP?

The filing shows beneficial holdings by 5AM Ventures VII, L.P. (2,941,176), 5AM Ventures VI, L.P. (2,625,145), and 5AM Opportunities II, L.P. (302,770).

Who are the individuals identified with shared voting or investment power in the CAMP filing?

The filing names Dr. Kush Parmar and Andrew J. Schwab as managing members of the relevant 5AM entities with shared voting and investment power; Mr. Schwab files separate reports as a director.

Does the Form 4 report any derivative transactions for CAMP?

No. The provided Table II for derivative securities contains no reported transactions; only non-derivative common stock purchases are listed.

When were the Form 4 signatures executed?

Signatures by the reporting entities and Kush Parmar are dated 09/15/2025 in the filing.